Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHABET Study
2020-005639-65Phase 3Active
- Sponsor
- GEICAM
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing alpelisib + trastuzumab +/- fulvestrant with trastuzumab + chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Jun 2021; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-005639-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005639-65.